tradingkey.logo
tradingkey.logo
Search

Penumbra Inc

PEN
Add to Watchlist
321.190USD
+1.430+0.45%
Close 07-31 16:00ETQuotes delayed by 15 min
12.63BMarket Cap
73.36P/E TTM

Penumbra Inc

321.190
+1.430+0.45%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+0.45%

5 Days

+0.77%

1 Month

+1.72%

6 Months

-10.32%

Year to Date

+3.31%

1 Year

+27.32%

Key Figures
323.050Open
323.050High
295.95KVolume
73.36P/E TTM
49.80P/E Dynamic
--Dividend TTM
0.75%Turnover Ratio
319.830Prev. Close
318.700Low
48.11MTurnover
901.43P/E Static
8.57P/B
0.00%Div Yield TTM
9.80%ROA
362.41052wk High
0.79Volume Ratio
14.01MNet Profit
39.32MShares
4.3781EPS TTM
0.71Beta
12.73%ROE
221.26052wk Low
1.36%Amplitude
67.93%Gross Margin
12.63BMarket Cap
0.30Reward/Risk
1.33%Risk Rate

TradingKey Stock Score of Penumbra Inc

Currency: USD Updated: 2026-07-31

Key Insights

Penumbra Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 368.53.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Penumbra Inc's Score

Industry at a Glance

Industry Ranking
53 / 199
Overall Ranking
118 / 4281
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Penumbra Inc Highlights

StrengthsRisks
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.61% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.40B.
Undervalued
The company’s latest PE is 73.36, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.73M shares, decreasing 6.29% quarter-over-quarter.
Held by George Soros
Star Investor George Soros holds 208.53K shares of this stock.

Analyst Rating

Based on 16 analysts
Hold
Current Rating
368.533
Target Price
+15.12%
Upside Space

Penumbra Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 16 analysts
Hold
Current Rating
368.533
Target Price
+15.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Penumbra Inc
PEN
16
Medtronic PLC
MDT
33
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
31
Stryker Corp
SYK
30
Abbott Laboratories
ABT
29
1
2
3
...
22

Indicators

Indicators
Sell(1)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.929
Neutral
RSI(14)
59.927
Neutral
STOCH(KDJ)(9,3,3)
74.152
Neutral
ATR(14)
2.210
Low Volatility
CCI(14)
143.154
Buy
Williams %R
25.272
Buy
TRIX(12,20)
0.016
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
320.126
Buy
MA10
318.916
Buy
MA20
318.444
Buy
MA50
319.096
Buy
MA100
324.552
Sell
MA200
315.627
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Penumbra Inc Info

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Ticker SymbolPEN
CompanyPenumbra Inc
CEOElsesser (Adam)
Websitehttps://www.penumbrainc.com/

Shareholders

Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.40%
BlackRock Institutional Trust Company, N.A.
9.09%
Vanguard Capital Management, LLC
4.31%
Vanguard Portfolio Management, LLC
4.21%
T. Rowe Price Associates, Inc.
4.09%
Other
66.92%

FAQs

What is the current price of Penumbra Inc (PEN)?

The current price of Penumbra Inc (PEN) is 321.25.

What is the symbol of Penumbra Inc?

The ticker symbol of Penumbra Inc is PEN.

What is the 52-week high of Penumbra Inc?

The 52-week high of Penumbra Inc is 362.41.

What is the 52-week low of Penumbra Inc?

The 52-week low of Penumbra Inc is 221.26.

What is the market capitalization of Penumbra Inc?

The market capitalization of Penumbra Inc is 12.63B.

Is Penumbra Inc (PEN) currently rated as Buy, Hold, or Sell?

According to analysts, Penumbra Inc (PEN) has an overall rating of signal_hold, with a price target of 368.53.

What is the Earnings Per Share (EPS TTM) of Penumbra Inc (PEN)?

The Earnings Per Share (EPS TTM) of Penumbra Inc (PEN) is 4.57.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.